The assay targets a specific tryptic peptide of NfL that is highly abundant across neurodegenerative and neuroinflammatory conditions, providing a reliable quantitation tool with utility across the full spectrum of neurological diseases. This evidence concerns the gene NEFL and nervous system disorder.